The Hatch-Waxman Act established a framework for generic and brand-name drugs to gain FDA approval. It created a pathway for generics to piggyback on original drug research and streamlined the approval process. The Act was later amended to prevent "pay for delay" deals between brand and generic companies that can delay cheaper generics entering the market.